Company Overview of The University of Massachusetts Medical School
55 Lake Avenue North
Worcester, MA 01655
Key Executives for The University of Massachusetts Medical School
Director for Diabetes Center of Excellence and Division Chief of Diabetes
Director for the Cancer Center of Excellence
Senior Director of Human Stem Cell Bank & Registry
Compensation as of Fiscal Year 2014.
The University of Massachusetts Medical School Key Developments
UMass Medical School Receives Multi-Million Dollar Contract to Manage Health Care at Federal Correctional Institution in New York
May 15 14
The Federal Bureau of Prisons has awarded the University of Massachusetts (UMass) Medical School a multimillion dollar contract to manage comprehensive medical services for nearly 1,000 inmates at the Federal Correctional Institution (FCI) located in Ray Brook, New York. The five-year agreement is valued at a total of $8 million, and becomes UMass Medical School's fourth federal correctional health contract. The Health and Criminal Justice Program, part of UMass Medical School's Commonwealth Medicine division, will manage the contract. The medical school's work at FCI Ray Brook will in the month June. The contract calls for UMass Medical School to coordinate inpatient and outpatient care provided by specialist physicians at the correctional facility and in community settings. The medical school will manage scheduling and handle all claims associated with the care.
University of Massachusetts Medical School Wins $7.98 Million Federal Contract
May 3 14
University of Massachusetts Medical School won a $7,979,958.52 federal contract from the U.S. Department of Justice's Bureau of Prisons, Grand Prairie, Texas, for comprehensive medical services.
Amarantus Bioscience Holdings, Inc Signs License Agreement with University of Massachusetts Medical School
Dec 18 13
Amarantus Bioscience Holdings Inc. has entered into an exclusive worldwide license agreement with University of Massachusetts Medical School (UMMS) for intellectual property surrounding the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) as both a biomarker and a treatment for beta cell-degenerating disorders. Both the entities are based in the US. The license agreement includes all intellectual property covering the use of MANF as a biomarker and treatment for beta cell degeneration disorders, including wolfram syndrome, Type-1 diabetes and Type-2 diabetes. Deal Rationale: The transaction expands Amarantus' intellectual property portfolio for MANF, including composition of matter and method of use patents and patent applications worldwide for MANF and derivative sequences for protein therapy, gene therapy and cell therapy applications.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries